Helicos BioSciences (HLCS) Names Lowy as CEO
More News related to HLCS
- Helicos BioSciences Presents an Overview of Single Molecule Sequencing Technology in Clinical Diagnostics
- Helicos BioSciences (HLCS) Announces Publication of Genome-Wide, Epigenomic Experiment Study
- Helicos and Mass General Hospital Publish Epigenomic Study in Nature Methods
- Helicos BioSciences (HLCS) Sells Genetic Analysis System to Dutch Research Collaborative
- Helicos BioSciences Announces the Sale of a Helicos(R) Genetic Analysis System to the Leiden University Medical Center in the Netherlands
More News related to Management Changes
- Dahlman Rose Initiates Coverage on Independent Oil & Gas Stocks
- Sandler O'Neill Initiates Coverage on AON Corp. (AON) with a Hold
- Ameriprise Financial Initiates Coverage on Janus Capital (JNS) with a Buy
- BGB Securities Initiates Coverage on International Flavors & Fragrances (IFF) with a Buy
- Barrington Research Initiates Coverage on Masimo (MASI) with an Outperform
Helicos BioSciences (NASDAQ: HLCS) announced today that its Board of Directors has appointed Ronald Lowy as the company's CEO, effective immediately.
Helicos BioSciences Corporation, a life sciences company, engages in the development of genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets.
Related Categories
Management ChangesStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
